At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMLX Amylyx Pharmaceuticals, Inc.
Post-Market Trading 05-21 17:48:19 EDT
1.80
-0.04
-2.17%
盘后1.79
-0.01-0.53%
17:41 EDT
High1.86
Low1.78
Vol894.74K
Open1.84
D1 Closing1.84
Amplitude4.35%
Mkt Cap122.41M
Tradable Cap92.75M
Total Shares68.01M
T/O1.62M
T/O Rate1.74%
Tradable Shares51.53M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Wave Life Sciences (WVE) and GoodRx Holdings (GDRX)
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.